Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment ; volume:49 ; number:2 ; day:8 ; month:2 ; year:2024 ; pages:229-237 ; date:3.2024
European journal of drug metabolism and pharmacokinetics ; 49, Heft 2 (8.2.2024), 229-237, 3.2024
- Creator
-
McCabe, James
Zhang, Jay
Yang, Fred
Benn, Vincent
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13318-024-00879-3
- URN
-
urn:nbn:de:101:1-2405070913436.407793716672
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McCabe, James
- Zhang, Jay
- Yang, Fred
- Benn, Vincent
- SpringerLink (Online service)
Other Objects (12)
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Effects of a novel non-steroidal mineralocorticoid receptor antagonist on cardiac hypertrophy
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
5074
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Effects of a novel non-steroidal mineralocorticoid receptor antagonist on cardiac hypertrophy
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
5074
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Effects of a novel non-steroidal mineralocorticoid receptor antagonist on cardiac hypertrophy
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury